Humberto Antunes, CEO of Galderma, has embraced our commercial team, and I know he will continue our efforts to build strong relationships with the healthcare leaders in this industry. Valeant Pharmaceuticals has sold the rights to injectables Restylane, Perlane, Emervel, Sculptra and Dysport to Galderma for $1.4bn. The sale was previously agreed with Nestlé, which recently acquired Galderma. In a statement, Galderma’s chief executive, Dr David Taylor, said: “While we are disappointed that our proposed acquisition of Galderma, Inc. is not going ahead, this transaction will allow us to continue developing
Valeant Pharmaceuticals has sold the rights to injectables Restylane, Perlane, Emervel, Sculptra and Dysport to Galderma for $1.4bn. The sale was previously agreed with Nestlé, which recently acquired Galderma. In a statement, Galderma’s chief executive, Dr David Taylor, said: “While we are disappointed that our proposed acquisition of Galderma, Inc. is not going ahead, this transaction will allow us to continue developing